-
Bristol-Myers Squibb NEW YORK STOCK EXCHANGE INC.:BMY Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Location: 430 E 29th St Fl 14, New York, 10016-8367, US | Website: www.bms.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
156.5B
Cash
8.094B
Avg Qtr Burn
N/A
Short % of Float
1.23%
Insider Ownership
0.12%
Institutional Own.
78.54%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KRAZATI (Adagrasib) + Cetuximab Details Cancer, Colorectal cancer , Solid tumor/s | Approved Quarterly sales | |
Opdivo® (nivolumab) + chemotherapy Details Cancer, Non-small cell lung carcinoma | Approved Quarterly sales | |
Reblozyl®(luspatercept-aamt) Details Cancer, Anemia, Blood cancer, Mutant Myelodysplastic Syndromes | Approved Quarterly sales | |
Camzyos®(mavacamten) Details Hypertrophic cardiomyopathies | Approved Quarterly sales | |
Zeposia (ozanimod) Details Multiple sclerosis, Ulcerative colitis | Approved Quarterly sales | |
Breyanzi® (lisocabtagene maraleucel) Details Chronic lymphocytic leukemia, Blood cancer, Small lymphocytic lymphoma | Approved Quarterly sales | |
Augtyro™ (Repotrectinib) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Quarterly sales | |
Breyanzi® (lisocabtagene maraleucel) Details Follicular lymphoma, Cancer | Approved Quarterly sales | |
KRAZATI (Adagrasib) Details Cancer, Lung cancer, Non-small cell lung carcinoma, Solid tumor/s, Colorectal cancer | Approved Quarterly sales | |
Opdivo® (nivolumab) Details Cancer, Melanoma | Approved Quarterly sales | |
Abecma (idecabtagene vicleucel) Details Cancer, Melanoma | Approved Quarterly sales | |
Eliquis Details Stroke, Atrial fibrillation, Blood clots | Approved Quarterly sales | |
Augtyro™ (Repotrectinib) Details Solid tumor/s, Cancer | Approved Quarterly sales | |
Opdivo® (nivolumab) + Cisplatin-Based Chemotherapy Details Cancer, Urothelial carcinoma | Approved Quarterly sales | |
Breyanzi® (lisocabtagene maraleucel) Details Mantle cell lymphoma, Cancer | Approved Quarterly sales | |
Sotyktu (deucravacitinib) Details Psoriasis, Skin disease/disorder | Approved Quarterly sales | |
Opdivo Qvantig™ Subcutaneous [(nivolumab + hyaluronidase (rHuPH20)] Details Cancer, Renal cell carcinoma | Approved Quarterly sales | |
COBENFY™ (xanomeline and trospium chloride) Details Mental health, Schizophrenia | Approved Quarterly sales | |
OPDIVO (nivolumab) injection Details Gastric cancer, Gastroesophageal adenocarcinomas | PDUFA Approval decision | |
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Hepatocellular carcinoma | PDUFA Approval decision | |
BMS-986278 [(LPA1) antagonist] Details Lung disease, Idiopathic pulmonary fibrosis | Phase 3 Data readout | |
Milvexian Details Acute coronary syndrome, Stroke, Atrial fibrillation | Phase 3 Data readout | |
KarXT (M1/M4 muscarinic agonist) Details Schizophrenia, Mental health, Alzheimer's disease | Phase 3 Data readout | |
KarXT (M1/M4 muscarinic agonist) Details Mental health, Schizophrenia | Phase 3 Data readout | |
Adagrasib (KRAZATI®) + Pembrolizumab Details Lung cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s | Phase 3 Update | |
Breyanzi® (lisocabtagene maraleucel) Details B-cell lymphoma | Phase 3 Update | |
KRAZATI (Adagrasib) Details Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s | Phase 3 Update | |
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Colorectal cancer , Cancer | Phase 3 Update | |
Opdivo® (nivolumab) + Yervoy (ipilimumab) Details Non-small cell lung carcinoma, Cancer | Phase 3 Update | |
Opdivo® (nivolumab) + relatlimab w/ ENHANZE® Details Cancer, Melanoma | Phase 3 Update | |
Sotyktu (deucravacitinib) Details Psoriatic arthritis | Phase 3 Update | |
Adagrasib (KRAZATI®) + Cetuximab Details Solid tumor/s, Colorectal cancer , Cancer | Phase 3 Update | |
Zeposia (ozanimod) Details Crohns disease | Phase 3 Update | |
Opdivo® (nivolumab) + Yervoy (ipilimumab) Copy Details Non-small cell lung carcinoma, Cancer | Phase 3 Update | |
A/I CELMoD (CC-99282) Details Relapsed/ refractory lymphoma, Non-Hodgkin lymphoma, Cancer | Phase 2 Interim update | |
Elzovantinib (TPX-0022) (MET inhibitor) Details Solid tumor/s, Cancer | Phase 2 Initiation | |
MRTX1719 (PRMT5 inhibitor) Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
Adagrasib (KRAZATI®) + MRTX0902 Details Solid tumor/s | Phase 1/2 Data readout | |
Golcadomide (CELMoD™ Agent) +rituximab Details Blood cancer, Diffuse large B cell lymphoma, Non-Hodgkin lymphoma | Phase 1/2 Update | |
MRTX1133 Details Cancer, Solid tumor/s, Colorectal cancer , Pancreatic cancer, Lung cancer | Phase 1/2 Update | |
Adagrasib (KRAZATI®) + VS-6766 Details Lung cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s | Phase 1/2 Initiation | |
Golcadomide (CELMoD™ Agent) Details Blood cancer, Non-Hodgkin lymphoma | Phase 1b Update | |
KarXT (M1/M4 muscarinic agonist) Details Schizophrenia, Mental health | Phase 1b Update | |
KAR-2618 Details Mental health, Major depressive disorder | Phase 1b Initiation | |
BMS-986393/CC-95266 Details High Refractory Multiple Myeloma | Phase 1 Update | |
BMS-986365 (CC-94676) Details Castration-resistant prostate cancer | Phase 1 Update |